Therapeutic monitoring of rivaroxaban in dogs using thromboelastography and prothrombin time

Therapeutic monitoring of rivaroxaban in dogs using thromboelastography and prothrombin time

Abstract Background The chromogenic anti‐Xa assay, the gold standard for monitoring the anti‐Xa effect of rivaroxaban, is not available as a cage‐side diagnostic test for use in a clinical setting. Hypothesis/Objectives To evaluate clinical modalities for measuring the anticoagulant effects of rivar...

Full description

Bibliographic Details
Main Authors:	Junwoo Bae, Hyunwoo Kim, Woosun Kim, Suhee Kim, Jinho Park, Dong‐In Jung, Dohyeon Yu
Format:	Article
Language:	English
Published:	Wiley 2019-05-01
Series:	Journal of Veterinary Internal Medicine
Subjects:	anti‐Xa oral anticoagulant point‐of‐care PT test TEG
Online Access:	https://doi.org/10.1111/jvim.15478

Similar Items

Case report: Severe hepatopathy following rivaroxaban administration in a dog
by: Allison P. Mosichuk, et al.
Published: (2024-04-01)

Incidence of platelet dysfunction by thromboelastography-platelet mapping in children supported with ECMO: A Pilot Retrospective Study.
by: Arun eSaini, et al.
Published: (2016-01-01)

Changes in Thromboelastography to Predict Ecchymosis After Knee Arthroplasty: A Promising Guide for the Use of Anticoagulants
by: Yuelong Chen, et al.
Published: (2022-04-01)

Idiosyncratic Liver Injury due to Rivaroxaban
by: Aneesh Cherakulam Ratheendran, et al.
Published: (2017-12-01)

Illustration: Thromboelastography – A useful tool to monitor COVID-19-associated coagulopathy
by: Ashwinkumar Vaidya, et al.
Published: (2022-01-01)

Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
by: Jing Tao, et al.
Published: (2018-06-01)

Evaluation of kaolin-activated thromboelastography and sample stability in healthy horses
by: K. Machackova, et al.
Published: (2018-05-01)

Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs
by: Noelle D. Herrera, et al.
Published: (2021-07-01)

Exploring microplastic impact on whole blood clotting dynamics utilizing thromboelastography
by: Alexei Christodoulides, et al.
Published: (2023-07-01)

Hyperthermic intraperitoneal chemotherapy enhances blood coagulation perioperatively evaluated by thromboelastography: a pilot study
by: Mari Tuovila, et al.
Published: (2020-01-01)

Urine-based point-of-care testing for factor-Xa-inhibitors in acute ischemic stroke patients: a feasibility study
by: Thorsten R. Doeppner, et al.
Published: (2023-12-01)

Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study
by: Tamana Meihandoest, et al.
Published: (2022-03-01)

Microplastic Effects on Thrombin–Fibrinogen Clotting Dynamics Measured via Turbidity and Thromboelastography
by: Daniela Q. Tran, et al.
Published: (2022-12-01)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
by: Dagmar eKubitza, et al.
Published: (2013-11-01)

APPLICATION OF RIVAROXABAN IN ACUTE CORONARY SYNDROME: EVIDENCE AND CURRENT GUIDELINES
by: O. V. Averkov
Published: (2016-01-01)

Thromboelastography in Microsurgical Reconstruction: A Systematic Review
by: M. Thakkar, et al.
Published: (2022-06-01)

Characterization of analytical errors in thromboelastography interpretation
by: Tapasyapreeti Mukhopadhyay, et al.
Published: (2021-01-01)

The evolution of clot strength in critically ill COVID-19 patients: a prospective observational thromboelastography study
by: Syed Nabeel Muzaffar, et al.
Published: (2022-02-01)

Rapid liquid chromatography tandem mass spectrometry determination of rivaroxaban levels in human plasma for therapeutic drug monitoring
by: Varga Andreea, et al.
Published: (2017-04-01)

Usefullness of Heparin Calibrated Anti-Xa Activity to Assess Anticoagulant Activity of Apixaban and Rivaroxaban in Emergency Patients Scheduled for Acute Interventions
by: Nada Riahi, et al.
Published: (2023-10-01)

Hemorrhagic herpes zoster with contralateral multidermatomal distribution associated with rivaroxaban: An unusual presentation
by: Josiah Sowell, BS, et al.
Published: (2021-03-01)

Intracranial hemorrhage in patient treated with rivaroxaban
by: Michelle Molina, et al.
Published: (2014-03-01)

Factor Xa Inhibition, A New Strategy for Prevention of Adverse Cardiac Remodeling in Early Stages?∗
by: Biykem Bozkurt, MD, PhD
Published: (2020-01-01)

Children with Iron Deficiency Anemia Have a Tendency to Hypercoagulation: An Evaluation by Thromboelastography
by: Ceren Kılcı, et al.
Published: (2020-02-01)

Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges
by: Ashley Chen, et al.
Published: (2020-07-01)

Fondaparinux Outpatient Use for Patients with a Heparin-Induced Thrombocytopenia History: A Case Report and Review
by: Amy Christopher
Published: (2016-12-01)

Electrochemical Monitoring in Anticoagulation Therapy
by: Ashwin K. V. Mruthunjaya, et al.
Published: (2024-03-01)

Rivaroxaban: Drug review
by: Abhishek Kumar Singh, et al.
Published: (2020-01-01)

Comparison of thromboelastography with routine laboratory coagulation parameters to assess the hemostatic profile and prognosticate postoperative critically ill patients
by: Amrita Bhattacharyya, et al.
Published: (2021-01-01)

Practical Nomogram Predicting Apixaban or Rivaroxaban Concentrations from Low-Molecular-Weight Heparin Anti-Xa Values: Special Interest in Acute Ischemic Stroke Patients
by: Charlyne Brakta, et al.
Published: (2023-01-01)

Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
by: George C. Leef, et al.
Published: (2017-11-01)

Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study
by: Savino Sciascia, et al.
Published: (2019-03-01)

Safety and Efficacy of Rivaroxaban as Extended-Phase Anticoagulation in Patients with Cancer and Venous Thromboembolism: A Preliminary Data Analysis from the Mac Project
by: Enrico Bernardi, et al.
Published: (2022-10-01)

Site-Of-Care Viscoelastic Assay in Major Trauma Improves Outcomes and Is Cost Neutral Compared with Standard Coagulation Tests
by: Catriona Cochrane, et al.
Published: (2020-07-01)

Rivaroxaban in acute venous thromboembolism: UK prescribing experience
by: Victoria Speed, et al.
Published: (2021-10-01)

Replacement of traditional prothrombin time monitoring with the new Fiix prothrombin time increases the efficacy of warfarin without increasing bleeding. A review article
by: Pall T. Onundarson, et al.
Published: (2021-10-01)

ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES
by: Z. M. Safiullina, et al.
Published: (2015-09-01)

Study of Modifications Induced by Continued Direct Oral Anticoagulant Therapy during Atrial Fibrillation Ablation Procedures on Standard Hemostasis Parameters
by: Marie Muller, et al.
Published: (2023-03-01)

Dental extractions on direct oral anticoagulants vs. warfarin: The DENTST study
by: Yvonne Brennan, et al.
Published: (2020-02-01)

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration
by: Priscila B. S. Serpa, et al.
Published: (2018-12-01)